0838 GMT - Bayer's prospects are improving, Berenberg analyst Sebastian Bray says in a note, citing a promising late-stage stroke prevention trial. Although the German pharmaceutical and agricultural conglomerate's late-stage trial for secondary stroke prevention is considered a long shot, there is a possibility of unexpected upside by the year end if the treatment proves significantly better than the placebo, the analyst says. "We believe there is an outside chance of a positive outcome for Bayer that may move the market's view of annual peak sales for the drug from very little to 1 billion euros or more," he says. In addition, if a Russia-Ukraine peace agreement doesn't cause a major drop in soft commodity prices, Bayer's earnings are unlikely to significantly decrease further, the analyst adds. Shares are up 1.7% at 23.65 euros. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
March 10, 2025 04:38 ET (08:38 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。